Friends of Cancer Research (Friends) is proud to announce a new virtual meeting, Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation. Breakthrough therapy designation is a process designed to expedite the development and review of drugs that are intended to treat serious conditions. In oncology, the ability to target a novel agent against key drivers of cancer has led to several therapeutic breakthroughs in serious, life-threatening diseases with limited or no systemic treatment options for cancer patients. These breakthroughs have established new classes of therapeutics leading to, in some instances, unprecedented efficacy results. 

This workshop will discuss best practices for optimizing interactions between the FDA and Sponsor to facilitate development of emerging new therapies and provide appropriate and timely access for patients. 

Link to register HERE.